Q-omics provides the consensus-scored CRACR2A profile across patient tissues and cancer cell-line models. CRACR2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CRACR2A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CRACR2A RNA expression shows 18,379 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where CRACR2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRACR2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRACR2A survival associations across molecular data types. CRACR2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRACR2A RNA expression–survival associations across cancer types. High CRACR2A expression shows unfavorable associations in UVM, LGG, UCS and CESC, but favorable associations in SCLC and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CRACR2A RNA expression.
This table summarizes CRACR2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CRACR2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRACR2A shows lower tumor expression in BRCA and higher tumor expression in KIRC, KIRP, LUAD, CHOL and LIHC. The KIRC box plot shows higher CRACR2A RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with CRACR2A in patient tissues and cancer cell lines. In patient samples, CRACR2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRACR2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
